tranexamic acid has been researched along with Disease Models, Animal in 55 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the role of bacterial- mediated plasminogen (PLG) activation in the pathogenesis of anastomotic leak (AL) and its mitigation by tranexamic acid (TXA)." | 8.02 | Prevention of Anastomotic Leak Via Local Application of Tranexamic Acid to Target Bacterial-mediated Plasminogen Activation: A Practical Solution to a Complex Problem. ( Alverdy, JC; Gaines, S; Hyoju, S; Jacobson, RA; Shogan, BD; van Goor, H; Wienholts, K; Williamson, AJ; Zaborin, A; Zaborina, O, 2021) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 7.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 7.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| "Intravenous (IV) tranexamic acid (TXA) is an adjunct for resuscitation in hemorrhagic shock; however, IV access in these patients may be difficult or impossible." | 7.91 | Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. ( Davidson, AJ; DeSoucy, ES; Ferencz, SE; Galante, JM; Grayson, JK; Hoareau, GL; Simon, MA; Tibbits, EM, 2019) |
| "It has been demonstrated that tranexamic acid (TXA), a synthetic derivative of lysine, alleviates lung damage in a trauma-hemorrhagic shock (T/HS) model." | 7.88 | Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats. ( Feng, C; Gao, Y; Jin, H; Li, T; Liu, Y; Teng, Y, 2018) |
| "Rats were exposed to experimental hemorrhagic shock (35 mm Hg mean arterial blood pressure for 2 hours, followed by reperfusion for 2 hours) and challenged with phenylephrine (2 μg/kg) at discrete intervals to measure vasopressor responsiveness." | 7.85 | Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock. ( Aletti, F; Chang, M; Kistler, EB; Leon, J; Li, JB; Santamaria, MH; Schmid-Schönbein, GW; Tan, A, 2017) |
| " We loaded these microparticles with thrombin and tranexamic acid and tested their efficacy in a swine arterial bleeding model without wound compression." | 7.83 | Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage. ( Baylis, JR; Chien, D; Kastrup, CJ; Liggins, RT; Lim, EB; Simonson, E; St John, AE; Statz, ML; Stern, SA; Wang, X; White, NJ, 2016) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 7.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective." | 7.77 | Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 7.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| "The effects of tranexamic acid, an inhibitor of plasminogen activator, were evaluated in a rabbit model of osteoarthritis induced by section of the knee joint anterior cruciate ligament." | 7.68 | Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis. ( Bejui, J; Descotes, J; Hartmann, D; Mathieu, P; Patricot, LM; Richard, M; Vignon, E, 1991) |
| "The chronic disease psoriasis is associated with severe inflammation and abnormal keratinocyte propagation in the skin." | 5.91 | Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies. ( Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR, 2023) |
| "Hemorrhage is responsible for 91% of preventable prehospital deaths in combat." | 5.91 | Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage. ( Ali-Mohamad, N; Baylis, JR; Beckett, A; Cau, MF; Kastrup, CJ; Khavari, A; Naveed, A; Peng, H; Peng, N; Ringgold, K; Semple, H; Sherwood, C; Tenn, C; Wang, X; White, NJ; Zhang Gao, H; Zhang, Y, 2023) |
| "The mechanisms for cardiac injury after hemorrhagic shock (HS) are unresolved." | 5.51 | Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock. ( Aletti, F; Chin, K; Kistler, EB; Mazor, R; Santamaria, M, 2019) |
| "Tranexamic acid (TnxAc) is an antifibrinolytic agent that is being increasingly used to prevent and control bleeding in conditions such as elective orthopedic surgery, trauma, and post-partum-hemorrhage, which are frequently followed by infection and sepsis." | 5.51 | Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model. ( Annichinno-Bizzacchi, JM; Campos Nogueira, YA; de Lima, F; De Paula, EV; Gomes da Costa, LN; Levy, CE; Orsi, FA, 2019) |
| "The TXA-loaded trauma-targeted nanovesicles (T-tNVs) were evaluated in vitro in rat blood, and then in vivo in a liver trauma model in rats." | 5.51 | Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model. ( Banerjee, A; Girish, A; Hickman, DA; Huang, S; Luc, N; Ma, Y; Miyazawa, K; Sekhon, UDS; Sen Gupta, A; Sun, M, 2019) |
| "Sprague-Dawley rats were subjected to polytrauma (laparotomy, and trauma to intestines, liver, right leg skeletal muscle, and right femur fracture), then bled 40% of their blood volume." | 5.46 | Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation. ( Cap, AP; Darlington, DN; Dubick, MA; Schwacha, MG; Wu, X, 2017) |
| "To investigate the role of bacterial- mediated plasminogen (PLG) activation in the pathogenesis of anastomotic leak (AL) and its mitigation by tranexamic acid (TXA)." | 4.02 | Prevention of Anastomotic Leak Via Local Application of Tranexamic Acid to Target Bacterial-mediated Plasminogen Activation: A Practical Solution to a Complex Problem. ( Alverdy, JC; Gaines, S; Hyoju, S; Jacobson, RA; Shogan, BD; van Goor, H; Wienholts, K; Williamson, AJ; Zaborin, A; Zaborina, O, 2021) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 3.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 3.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| " Administering tranexamic acid (TXA), an antifibrinolytic agent, is one strategy to reduce bleeding; however, it must be given soon after injury to be effective and minimize adverse effects." | 3.91 | Topical tranexamic acid inhibits fibrinolysis more effectively when formulated with self-propelling particles. ( Baylis, JR; Cau, M; Gusti, V; Kastrup, CJ; Kazerooni, A; Lee, MM; Liggins, RT; Simonson, E; St John, AE; Statz, ML; Wang, X; White, NJ; Yoon, JSJ, 2019) |
| "Intravenous (IV) tranexamic acid (TXA) is an adjunct for resuscitation in hemorrhagic shock; however, IV access in these patients may be difficult or impossible." | 3.91 | Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. ( Davidson, AJ; DeSoucy, ES; Ferencz, SE; Galante, JM; Grayson, JK; Hoareau, GL; Simon, MA; Tibbits, EM, 2019) |
| "It has been demonstrated that tranexamic acid (TXA), a synthetic derivative of lysine, alleviates lung damage in a trauma-hemorrhagic shock (T/HS) model." | 3.88 | Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats. ( Feng, C; Gao, Y; Jin, H; Li, T; Liu, Y; Teng, Y, 2018) |
| "Rats were exposed to experimental hemorrhagic shock (35 mm Hg mean arterial blood pressure for 2 hours, followed by reperfusion for 2 hours) and challenged with phenylephrine (2 μg/kg) at discrete intervals to measure vasopressor responsiveness." | 3.85 | Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock. ( Aletti, F; Chang, M; Kistler, EB; Leon, J; Li, JB; Santamaria, MH; Schmid-Schönbein, GW; Tan, A, 2017) |
| " We loaded these microparticles with thrombin and tranexamic acid and tested their efficacy in a swine arterial bleeding model without wound compression." | 3.83 | Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage. ( Baylis, JR; Chien, D; Kastrup, CJ; Liggins, RT; Lim, EB; Simonson, E; St John, AE; Statz, ML; Stern, SA; Wang, X; White, NJ, 2016) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 3.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective." | 3.77 | Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 3.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| " This series of studies tested whether these drugs (aprotinin, desmopressin, tranexamic acid, epsilon-aminocaproic acid) could reduce bleeding due to traumatic injuries in two models of uncontrolled hemorrhage in rats." | 3.73 | Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage. ( Cortez, DS; Dick, EJ; Pusateri, AE; Ryan, KL, 2006) |
| "The effects of tranexamic acid, an inhibitor of plasminogen activator, were evaluated in a rabbit model of osteoarthritis induced by section of the knee joint anterior cruciate ligament." | 3.68 | Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis. ( Bejui, J; Descotes, J; Hartmann, D; Mathieu, P; Patricot, LM; Richard, M; Vignon, E, 1991) |
| "The chronic disease psoriasis is associated with severe inflammation and abnormal keratinocyte propagation in the skin." | 1.91 | Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies. ( Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR, 2023) |
| "Hemorrhage is responsible for 91% of preventable prehospital deaths in combat." | 1.91 | Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage. ( Ali-Mohamad, N; Baylis, JR; Beckett, A; Cau, MF; Kastrup, CJ; Khavari, A; Naveed, A; Peng, H; Peng, N; Ringgold, K; Semple, H; Sherwood, C; Tenn, C; Wang, X; White, NJ; Zhang Gao, H; Zhang, Y, 2023) |
| "Trauma and hemorrhagic shock (T/HS) is a major cause of morbidity and mortality." | 1.72 | Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock. ( Aletti, F; DeLano, FA; Kistler, EB; Maffioli, E; Mu, H; Schmid-Schönbein, GW; Tedeschi, G, 2022) |
| "Mice were then subjected to controlled hemorrhagic shock for 1 h to a goal MAP of 25 mmHg." | 1.72 | MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE. ( Baucom, MR; England, LG; Goodman, MD; Pritts, TA; Schuster, RM; Wallen, TE, 2022) |
| "The mechanisms for cardiac injury after hemorrhagic shock (HS) are unresolved." | 1.51 | Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock. ( Aletti, F; Chin, K; Kistler, EB; Mazor, R; Santamaria, M, 2019) |
| "The TXA-loaded trauma-targeted nanovesicles (T-tNVs) were evaluated in vitro in rat blood, and then in vivo in a liver trauma model in rats." | 1.51 | Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model. ( Banerjee, A; Girish, A; Hickman, DA; Huang, S; Luc, N; Ma, Y; Miyazawa, K; Sekhon, UDS; Sen Gupta, A; Sun, M, 2019) |
| "Tranexamic acid (TnxAc) is an antifibrinolytic agent that is being increasingly used to prevent and control bleeding in conditions such as elective orthopedic surgery, trauma, and post-partum-hemorrhage, which are frequently followed by infection and sepsis." | 1.51 | Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model. ( Annichinno-Bizzacchi, JM; Campos Nogueira, YA; de Lima, F; De Paula, EV; Gomes da Costa, LN; Levy, CE; Orsi, FA, 2019) |
| "The non-mucosal bleeding phenotype in hemophilia A appears largely unaffected by fibrinolysis." | 1.48 | Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents. ( Bojko, B; Flick, MJ; Goryńska, PZ; Goryński, K; Knudsen, T; Ley, CD; Olsen, LH; Stagaard, R, 2018) |
| "Mean 25% of the present 2017 Joint Trauma System Clinical Practice Guideline dosing of TXA can be lost to hemorrhage if a blood volume is transfused within an hour of initiating therapy." | 1.48 | The effects of hemorrhage on the pharmacokinetics of tranexamic acid in a swine model. ( Barron, MR; Derickson, MJ; Kuckelman, JP; Loughren, MJ; Marko, ST; Martin, MJ; McClellan, JM; Phillips, CJ, 2018) |
| "Sprague-Dawley rats were subjected to polytrauma (laparotomy, and trauma to intestines, liver, right leg skeletal muscle, and right femur fracture), then bled 40% of their blood volume." | 1.46 | Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation. ( Cap, AP; Darlington, DN; Dubick, MA; Schwacha, MG; Wu, X, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic with anti-inflammatory properties associated with improved outcomes when administered to trauma patients at risk for bleeding; however, its efficacy is unknown in acidemia." | 1.40 | Tranexamic acid corrects fibrinolysis in the presence of acidemia in a swine model of severe ischemic reperfusion. ( DeBarros, M; DuBose, J; Eckert, M; Hatch, Q; Izenberg, S; Martin, M; Porta, CR; Salgar, S, 2014) |
| "Treatment with tranexamic acid inhibited plasmin generation and abrogated enhanced AAA progression in pCPB(-/-) mice." | 1.36 | Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. ( Dalman, RL; Du, X; Leung, LL; Morser, J; Myles, T; Nishimura, T; Schultz, G; Sharif, S; Sho, E; Tedesco, MM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (10.91) | 18.2507 |
| 2000's | 4 (7.27) | 29.6817 |
| 2010's | 35 (63.64) | 24.3611 |
| 2020's | 10 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Wallen, TE | 1 |
| Baucom, MR | 1 |
| England, LG | 1 |
| Schuster, RM | 1 |
| Pritts, TA | 1 |
| Goodman, MD | 1 |
| Hseu, JH | 1 |
| Chan, CI | 1 |
| Vadivalagan, C | 1 |
| Chen, SJ | 1 |
| Yen, HR | 1 |
| Hseu, YC | 1 |
| Yang, HL | 1 |
| Wu, PY | 1 |
| Ali-Mohamad, N | 1 |
| Cau, MF | 1 |
| Wang, X | 3 |
| Khavari, A | 1 |
| Ringgold, K | 1 |
| Naveed, A | 1 |
| Sherwood, C | 1 |
| Peng, N | 1 |
| Zhang Gao, H | 1 |
| Zhang, Y | 1 |
| Semple, H | 1 |
| Peng, H | 1 |
| Tenn, C | 1 |
| Baylis, JR | 3 |
| Beckett, A | 1 |
| White, NJ | 3 |
| Kastrup, CJ | 3 |
| Spruce, MW | 1 |
| Beyer, CA | 1 |
| Caples, CM | 1 |
| DeSoucy, ES | 2 |
| Kashtan, HW | 1 |
| Hoareau, GL | 2 |
| Grayson, JK | 2 |
| Johnson, MA | 1 |
| Draxler, DF | 2 |
| Daglas, M | 2 |
| Fernando, A | 1 |
| Hanafi, G | 2 |
| McCutcheon, F | 1 |
| Ho, H | 2 |
| Galle, A | 2 |
| Gregory, J | 1 |
| Larsson, P | 1 |
| Keragala, C | 2 |
| Wright, DK | 1 |
| Tavancheh, E | 1 |
| Au, AE | 1 |
| Niego, B | 1 |
| Wilson, K | 1 |
| Plebanski, M | 1 |
| Sashindranath, M | 2 |
| Medcalf, RL | 2 |
| Wu, X | 2 |
| Benov, A | 1 |
| Darlington, DN | 2 |
| Keesee, JD | 1 |
| Liu, B | 1 |
| Cap, AP | 2 |
| Jacobson, RA | 2 |
| Wienholts, K | 2 |
| Williamson, AJ | 2 |
| Gaines, S | 2 |
| Hyoju, S | 2 |
| van Goor, H | 2 |
| Zaborin, A | 2 |
| Shogan, BD | 2 |
| Zaborina, O | 2 |
| Alverdy, JC | 2 |
| Campos Nogueira, YA | 1 |
| Gomes da Costa, LN | 1 |
| Levy, CE | 1 |
| Orsi, FA | 1 |
| de Lima, F | 1 |
| Annichinno-Bizzacchi, JM | 1 |
| De Paula, EV | 1 |
| Davidson, AJ | 1 |
| Simon, MA | 1 |
| Tibbits, EM | 1 |
| Ferencz, SE | 1 |
| Galante, JM | 1 |
| Wang, Y | 1 |
| Xie, R | 1 |
| Li, Q | 1 |
| Dai, F | 1 |
| Lan, G | 1 |
| Shang, S | 1 |
| Lu, F | 1 |
| Sarı, A | 1 |
| Dinçel, YM | 1 |
| Karabağ, S | 1 |
| Çetin, MÜ | 1 |
| Aletti, F | 3 |
| DeLano, FA | 1 |
| Maffioli, E | 1 |
| Mu, H | 1 |
| Schmid-Schönbein, GW | 2 |
| Tedeschi, G | 1 |
| Kistler, EB | 3 |
| Santamaria, MH | 1 |
| Li, JB | 1 |
| Tan, A | 1 |
| Chang, M | 1 |
| Leon, J | 1 |
| Lallemand, MS | 1 |
| Moe, DM | 1 |
| McClellan, JM | 2 |
| Loughren, M | 1 |
| Marko, S | 1 |
| Eckert, MJ | 1 |
| Martin, MJ | 3 |
| Teng, Y | 1 |
| Feng, C | 1 |
| Liu, Y | 1 |
| Jin, H | 1 |
| Gao, Y | 1 |
| Li, T | 1 |
| Stagaard, R | 1 |
| Flick, MJ | 1 |
| Bojko, B | 1 |
| Goryński, K | 1 |
| Goryńska, PZ | 1 |
| Ley, CD | 1 |
| Olsen, LH | 1 |
| Knudsen, T | 1 |
| Derickson, MJ | 1 |
| Marko, ST | 1 |
| Kuckelman, JP | 1 |
| Phillips, CJ | 1 |
| Barron, MR | 1 |
| Loughren, MJ | 1 |
| Fallah, M | 1 |
| Shen, Y | 1 |
| Brodén, J | 1 |
| Bäckman, A | 1 |
| Lundskog, B | 1 |
| Johansson, M | 1 |
| Blomquist, M | 1 |
| Liu, K | 1 |
| Wilczynska, M | 1 |
| Ny, T | 1 |
| Jing, J | 1 |
| Du, Z | 1 |
| Wen, Z | 1 |
| Jiang, B | 1 |
| He, B | 1 |
| Carter, DW | 1 |
| Prudovsky, I | 1 |
| Kacer, D | 1 |
| Soul, T | 1 |
| Kumpel, C | 1 |
| Pyburn, K | 1 |
| Palmeri, M | 1 |
| Kramer, R | 1 |
| Rappold, J | 1 |
| Santamaria, M | 1 |
| Chin, K | 1 |
| Mazor, R | 1 |
| Awad, MM | 1 |
| Roquilly, A | 1 |
| Lyras, D | 1 |
| Lee, MM | 1 |
| St John, AE | 2 |
| Simonson, E | 2 |
| Cau, M | 1 |
| Kazerooni, A | 1 |
| Gusti, V | 1 |
| Statz, ML | 2 |
| Yoon, JSJ | 1 |
| Liggins, RT | 2 |
| Girish, A | 1 |
| Hickman, DA | 1 |
| Banerjee, A | 1 |
| Luc, N | 1 |
| Ma, Y | 1 |
| Miyazawa, K | 1 |
| Sekhon, UDS | 1 |
| Sun, M | 1 |
| Huang, S | 1 |
| Sen Gupta, A | 1 |
| Chapela, D | 1 |
| Sousa, S | 1 |
| Martins, I | 1 |
| Cristóvão, AM | 1 |
| Pinto, P | 1 |
| Corte-Real, S | 1 |
| Saúde, L | 1 |
| Hsieh, PW | 1 |
| Chen, WY | 1 |
| Aljuffali, IA | 1 |
| Chen, CC | 1 |
| Fang, JY | 1 |
| Porta, CR | 2 |
| Nelson, D | 1 |
| McVay, D | 1 |
| Salgar, S | 2 |
| Eckert, M | 2 |
| Izenberg, S | 2 |
| Kratzer, S | 1 |
| Irl, H | 1 |
| Mattusch, C | 1 |
| Bürge, M | 1 |
| Kurz, J | 1 |
| Kochs, E | 1 |
| Eder, M | 1 |
| Rammes, G | 1 |
| Haseneder, R | 1 |
| DeBarros, M | 1 |
| Hatch, Q | 1 |
| DuBose, J | 1 |
| Martin, M | 1 |
| Joshi, N | 1 |
| Kopec, AK | 1 |
| Towery, K | 1 |
| Williams, KJ | 1 |
| Luyendyk, JP | 1 |
| Honickel, M | 2 |
| Treutler, S | 1 |
| van Ryn, J | 1 |
| Tillmann, S | 1 |
| Rossaint, R | 2 |
| Grottke, O | 2 |
| Tuttle, JR | 1 |
| Feltman, PR | 1 |
| Ritterman, SA | 1 |
| Ehrlich, MG | 1 |
| Zentai, C | 1 |
| van der Meijden, PE | 1 |
| Braunschweig, T | 1 |
| Hueck, N | 1 |
| Spronk, HM | 1 |
| Lim, EB | 1 |
| Chien, D | 1 |
| Stern, SA | 1 |
| Dubick, MA | 1 |
| Schwacha, MG | 1 |
| Boysen, SR | 1 |
| Pang, JM | 1 |
| Mikler, JR | 1 |
| Knight, CG | 1 |
| Semple, HA | 1 |
| Caulkett, NA | 1 |
| R Baylis, J | 1 |
| Finkelstein-Kulka, A | 1 |
| Macias-Valle, L | 1 |
| Manji, J | 1 |
| Lee, M | 1 |
| Levchenko, E | 1 |
| Okpaleke, C | 1 |
| Al-Salihi, S | 1 |
| Javer, A | 1 |
| J Kastrup, C | 1 |
| Roy, M | 1 |
| Burggraf, M | 1 |
| Lendemans, S | 1 |
| de Groot, H | 1 |
| Rohrig, R | 1 |
| Wiseman, DM | 1 |
| Meidler, R | 1 |
| Lyahovetsky, Y | 1 |
| Kurman, E | 1 |
| Horn, S | 1 |
| Nur, I | 1 |
| Schultz, G | 1 |
| Tedesco, MM | 1 |
| Sho, E | 1 |
| Nishimura, T | 1 |
| Sharif, S | 1 |
| Du, X | 1 |
| Myles, T | 1 |
| Morser, J | 1 |
| Dalman, RL | 1 |
| Leung, LL | 1 |
| Bajaj, MS | 1 |
| Ogueli, GI | 1 |
| Kumar, Y | 1 |
| Vadivel, K | 1 |
| Lawson, G | 1 |
| Shanker, S | 1 |
| Schmidt, AE | 1 |
| Bajaj, SP | 1 |
| Illanes, S | 1 |
| Zhou, W | 1 |
| Schwarting, S | 1 |
| Heiland, S | 1 |
| Veltkamp, R | 1 |
| Li, D | 1 |
| Li, P | 1 |
| Zang, J | 1 |
| Liu, J | 1 |
| Ryan, KL | 1 |
| Cortez, DS | 1 |
| Dick, EJ | 1 |
| Pusateri, AE | 1 |
| Swaisgood, CM | 1 |
| Aronica, MA | 1 |
| Swaidani, S | 1 |
| Plow, EF | 1 |
| Paul, J | 1 |
| Strickland, S | 1 |
| Melchor, JP | 1 |
| Moriuchi, H | 2 |
| Yuizono, T | 2 |
| Arai, I | 1 |
| Ishizuka, Y | 1 |
| Kamisaki, T | 1 |
| Okamoto, H | 1 |
| Kawashima, M | 1 |
| Sato, M | 1 |
| Vankemmel, O | 1 |
| de La Taille, A | 1 |
| Burnouf, T | 1 |
| Rigot, JM | 1 |
| Duchene, F | 1 |
| Mazeman, E | 1 |
| Okamoto, S | 1 |
| Wanaka, K | 1 |
| Hijikata-Okunomiya, A | 1 |
| Okada, Y | 1 |
| Katsuura, Y | 1 |
| Vignon, E | 1 |
| Mathieu, P | 1 |
| Bejui, J | 1 |
| Descotes, J | 1 |
| Hartmann, D | 1 |
| Patricot, LM | 1 |
| Richard, M | 1 |
| Moser, KM | 1 |
| Cantor, JP | 1 |
| Olman, M | 1 |
| Villespin, I | 1 |
| Graif, JL | 1 |
| Konopka, R | 1 |
| Marsh, JJ | 1 |
| Pedersen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
55 other studies available for tranexamic acid and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE.
Topics: Animals; Biomarkers; Brain Injuries; Brain Injuries, Traumatic; Chemokine CCL3; Combined Modality Th | 2022 |
Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies.
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammasomes; Inflammation; Interle | 2023 |
Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage.
Topics: Animals; Bandages; Blindness; Disease Models, Animal; Hemorrhage; Hemostatic Techniques; Hemostatics | 2023 |
Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Female; Hemorrhage; Infusions, Intravenous | 2020 |
Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
Topics: Animals; Antifibrinolytic Agents; Brain; Brain Injuries, Traumatic; Cell Proliferation; Chemotaxis, | 2019 |
Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Biomarkers; Blood Coagulation; Blood Coagulation Disorders; Diseas | 2019 |
Topics: Animals; Anti-Bacterial Agents; Antifibrinolytic Agents; Collagen Type I; Collagen Type IV; Colon; D | 2020 |
Prevention of Anastomotic Leak Via Local Application of Tranexamic Acid to Target Bacterial-mediated Plasminogen Activation: A Practical Solution to a Complex Problem.
Topics: Anastomotic Leak; Animals; Collagen; Colon; Disease Models, Animal; Enema; Enterococcus faecalis; Mi | 2021 |
Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model.
Topics: Animals; Antifibrinolytic Agents; Biomarkers; Cecum; Coinfection; Cytokines; Disease Models, Animal; | 2019 |
Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model.
Topics: Administration, Intravenous; Animals; Disease Models, Animal; Humans; Infusions, Intraosseous; Injec | 2019 |
A self-adapting hydrogel based on chitosan/oxidized konjac glucomannan/AgNPs for repairing irregular wounds.
Topics: Animals; Cell Line; Chitosan; Disease Models, Animal; Escherichia coli; Hydrogels; Mannans; Metal Na | 2020 |
Histopathological and immunohistochemical investigation of the local and systemic effects of tranexamic acid on the healing of the Achilles tendon in rats.
Topics: Achilles Tendon; Animals; Antifibrinolytic Agents; Collagen Type I; Collagen Type III; Disease Model | 2021 |
Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock.
Topics: Animals; Disease Models, Animal; Humans; Intestine, Small; Ischemia; Protease Inhibitors; Rats; Rats | 2022 |
Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock.
Topics: Animals; Blood Pressure; Disease Models, Animal; Drug Resistance; Fluid Therapy; Hemodynamics; Injec | 2017 |
No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Infusion | 2018 |
Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Disease Models, | 2018 |
Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Topics: Animals; Antifibrinolytic Agents; Coagulants; Disease Models, Animal; Factor VIIa; Factor VIII; Fibr | 2018 |
The effects of hemorrhage on the pharmacokinetics of tranexamic acid in a swine model.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Exsanguination; Hypovolemia; Infusions, In | 2018 |
Plasminogen activation is required for the development of radiation-induced dermatitis.
Topics: Animals; Cell Movement; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation; Heter | 2018 |
Dynamic changes of urinary proteins in a rat model of acute hypercoagulable state induced by tranexamic acid.
Topics: Acute Disease; Animals; Biomarkers; Blood Coagulation; Chromatography, High Pressure Liquid; Disease | 2019 |
Tranexamic acid suppresses the release of mitochondrial DAMPs and reduces lung inflammation in a murine burn model.
Topics: Administration, Topical; Alarmins; Animals; Burns; Disease Models, Animal; DNA, Mitochondrial; Male; | 2019 |
Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock.
Topics: Administration, Oral; Animals; Antifibrinolytic Agents; CD36 Antigens; Disease Models, Animal; Fatty | 2019 |
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Topics: Animals; Antifibrinolytic Agents; Brain Injuries, Traumatic; Disease Models, Animal; Immunity, Cellu | 2019 |
Topical tranexamic acid inhibits fibrinolysis more effectively when formulated with self-propelling particles.
Topics: Administration, Topical; Animals; Antifibrinolytic Agents; Calcium Carbonate; Carbon Dioxide; Diseas | 2019 |
Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model.
Topics: Animals; Antifibrinolytic Agents; Blood Platelets; Disease Models, Animal; Fibrinogen; Hemorrhage; H | 2019 |
A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals.
Topics: Animals; Cycloserine; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Female; | 2019 |
Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid.
Topics: Administration, Cutaneous; Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug Com | 2013 |
The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis.
Topics: Acidosis; Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; | 2013 |
Tranexamic acid impairs γ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures?
Topics: Amygdala; Animals; Antifibrinolytic Agents; Disease Models, Animal; Electric Stimulation; Male; Mice | 2014 |
Tranexamic acid corrects fibrinolysis in the presence of acidemia in a swine model of severe ischemic reperfusion.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Fibrinolysis; Recombinant Proteins; Resusc | 2014 |
The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.
Topics: 1-Naphthylisothiocyanate; Animals; Antifibrinolytic Agents; Bile Duct Diseases; Collagen Type I; Dis | 2014 |
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Antifibrinolytic Agents; Antithrom | 2015 |
Effects of Tranexamic Acid Cytotoxicity on In Vitro Chondrocytes.
Topics: Animals; Apoptosis; Cattle; Cell Survival; Cells, Cultured; Chondrocytes; Disease Models, Animal; Do | 2015 |
Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
Topics: Abdominal Injuries; Animals; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Factors; | 2016 |
Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage.
Topics: Animals; Bandages; Disease Models, Animal; Female; Hemorrhage; Hemostatics; Models, Statistical; Swi | 2016 |
Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Hemorrhage; Lung; Male; Multiple Trauma; Rats; R | 2017 |
Comparison of tranexamic acid plasma concentrations when administered via intraosseous and intravenous routes.
Topics: Animals; Antifibrinolytic Agents; Blood Gas Analysis; Disease Models, Animal; Infusions, Intraosseou | 2017 |
Rapid hemostasis in a sheep model using particles that propel thrombin and tranexamic acid.
Topics: Animals; Blood Loss, Surgical; Carotid Artery Injuries; Disease Models, Animal; Hemostatic Technique | 2017 |
Tranexamic acid prolongs survival after controlled hemorrhage in rats.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolysis | 2017 |
Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci.
Topics: Animals; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Female; Fibrin; He | 2010 |
Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice.
Topics: Animals; Antifibrinolytic Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Car | 2010 |
Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.
Topics: Amino Acid Substitution; Animals; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Factors; Dis | 2011 |
Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Cerebral Hemorrhage; Collagenases; Disease Model | 2011 |
Enhanced hemostatic performance of tranexamic acid-loaded chitosan/alginate composite microparticles.
Topics: Absorption; Alginates; Animals; Cell Death; Cell Shape; Chitosan; Disease Models, Animal; Female; Fi | 2012 |
Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Aprotinin; Deamino Arginine Vasopressin; Diseas | 2006 |
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Topics: Animals; Antifibrinolytic Agents; Asthma; Bronchoalveolar Lavage Fluid; Collagen; Disease Models, An | 2007 |
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Disease Models, Animal; Disease Progression; Fibrin | 2007 |
[Oleic acid-induced PaO2 decrease model for primary screening of drugs for hypoxemia: effects of tranexamic acid and procaterol hydrochloride on the decrease in PaO2].
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Guinea Pigs; Hypoxia; Male; Oleic Aci | 1994 |
Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation.
Topics: Analysis of Variance; Animals; Capillary Permeability; Diphenhydramine; Disease Models, Animal; Dose | 1995 |
Effect of 1,6-dihydro-2[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidineca rboxyli c acid on ethanol-induced microvascular injury in rats.
Topics: Animals; Anti-Ulcer Agents; Capillary Permeability; Disease Models, Animal; Ethanol; Gastric Mucosa; | 1996 |
Evaluation of a fibrin sealant free of bovine-derived components in an experimental vas anastomosis study.
Topics: Anastomosis, Surgical; Animals; Cattle; Disease Models, Animal; Fibrin Tissue Adhesive; Male; Materi | 2000 |
A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC.
Topics: Animals; Blood Coagulation; Bradykinin; Disease Models, Animal; Disseminated Intravascular Coagulati | 1992 |
Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis.
Topics: Animals; Cartilage, Articular; Disease Models, Animal; Female; Hypertrophy; Injections, Intramuscula | 1991 |
Chronic pulmonary thromboembolism in dogs treated with tranexamic acid.
Topics: Animals; Disease Models, Animal; Dogs; Hypertension, Pulmonary; Premedication; Pulmonary Embolism; T | 1991 |